Keywords: Geriatrics; DMARDs; Rheumatology; Rheumatoid arthritis; Tofacitinib; Apremilast;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: apremilast; cost per responder; cost-effectiveness; indirect comparison; methotrexate; moderate to severe psoriasis; number needed to treat; Psoriasis Area and Severity Index; AAD; American Academy of Dermatology; CI; confidence interval; FDA; Food and Dr
Keywords: Psoriasis; Methotrexate; Cyclosporine; Acitretin; Apremilast; Tofacitinib; Mycophenolate mofetil;
Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways
Keywords: Apremilast; Inflammation; Cardiotoxicity; Doxorubicin; Nuclear factor-kappa B;
Solubility and thermodynamics of apremilast in different mono solvents: Determination, correlation and molecular interactions
Keywords: Apremilast; Activity coefficient; Antipsoriatic arthritis; Dissolution thermodynamics; Mono solvent; Solubility;
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for â¥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Keywords: apremilast; clinical trial; ESTEEM; phosphodiesterase 4 inhibitor; psoriasis; psoriatic arthritis; safety; AE; adverse event; EAIR; exposure-adjusted incidence rate; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; GI;
Solubility and thermodynamic function of apremilast in different (Transcutol + water) cosolvent mixtures: Measurement, correlation and molecular interactions
Keywords: Apremilast; Activity coefficient; Cosolvent mixture; Solubility; Thermodynamics;
Identification and characterization of process-related substances and degradation products in apremilast: Process optimization and degradation pathway elucidation
Keywords: Apremilast; Related substances; LC-MS; Process optimization;
The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells
Keywords: cAMP; cyclic adenosine monophosphate; slanDC; 6-Sulfo LacNAc-expressing dendritic; cells PDE; phosphodiesterase; Th17; T helper cells producing interleukin 17; Th1; T helper cells producing interferon gamma; TNF-α; Tumor necrosis factor alpha; iNOS; indu
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical
Keywords: apremilast; difficult to treat; ESTEEM; moderate to severe; palmoplantar psoriasis; palms; PSOR-005; soles; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; IL; interleukin; m-PPPASI; modified Palmoplantar Psoriasis Are
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)
Keywords: apremilast; nail psoriasis; phosphodiesterase 4 inhibitor; psoriasis; scalp psoriasis; systemic therapy; BID; twice daily; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; NAPSI; Nail Psoriasis Severity Index; NAPSI-50;
Treatment of spondyloarthritis beyond TNF-alpha blockade
Keywords: Spondyloarthritis; Psoriatic arthritis; Axial spondyloarthritis; Ankylosing spondylitis; Anti-TNF failure; Ustekinumab; Anti-interleukin-17 agents; Apremilast
An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series
Keywords: apremilast; interferon-γ; interleukin; leukotriene B4; lichen planus; treatment; tumor necrosis factor-αAE, adverse event; ANA, antinuclear antibody; DLQI, Dermatology Life Quality Index; IL, interleukin; LP, lichen planus; PGA, Physician Global Assessmen